Cytokines and persistent viral infections

Cytokine

Volumn 82, Issue , 2016, Pages 4-15

  Beltra, Jean Christophe ^a,b   Decaluwe, Hélène ^a,b  

^a UNIVERSITY OF MONTREAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Chronic viral infection; Cytokine; Exhaustion; T cell

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 11; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 21; INTERLEUKIN 27; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 9; LEUKEMIA INHIBITORY FACTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; ONCOSTATIN M; STAT1 PROTEIN; STAT3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ANTIGEN EXPRESSION; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; HUMAN; HUMORAL IMMUNITY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; NONHUMAN; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVIEW; VIRAL CLEARANCE; VIRUS NEUTRALIZATION; VIRUS REPLICATION; ANIMAL; CHRONIC DISEASE; IMMUNOLOGY; MOUSE; T LYMPHOCYTE; VIRUS INFECTION;

ANIMALS; CHRONIC DISEASE; CYTOKINES; HUMANS; IMMUNITY, CELLULAR; MICE; T-LYMPHOCYTES; VIRUS DISEASES;

EID: 84958580510     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2016.02.006     Document Type: Review

References (218)

1. Kaech S.M., Cui W. Transcriptional control of effector and memory CD8+ T cell differentiation. Nat. Rev. Immunol. 2012, 12:749-761.
2. Wherry E.J. T cell exhaustion. Nat. Immunol. 2011, 12:492-499.
3. Wherry E.J., Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat. Rev. Immunol. 2015, 15:486-499.
4. Wherry E.J., Ha S.J., Kaech S.M., Haining W.N., Sarkar S., Kalia V., et al. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity 2007, 27:670-684.
5. Blackburn S.D., Shin H., Haining W.N., Zou T., Workman C.J., Polley A., et al. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat. Immunol. 2009, 10:29-37.
6. Odorizzi P.M., Wherry E.J. Inhibitory receptors on lymphocytes: insights from infections. J. Immunol. 2012, 188:2957-2965.
7. Shin H., Blackburn S.D., Blattman J.N., Wherry E.J. Viral antigen and extensive division maintain virus-specific CD8 T cells during chronic infection. J. Exp. Med. 2007, 204:941-949.
8. Wherry E.J., Barber D.L., Kaech S.M., Blattman J.N., Ahmed R. Antigen-independent memory CD8 T cells do not develop during chronic viral infection. Proc. Natl. Acad. Sci. USA 2004, 101:16004-16009.
9. Crawford A., Angelosanto J.M., Kao C., Doering T.A., Odorizzi P.M., Barnett B.E., et al. Molecular and transcriptional basis of CD4(+) T cell dysfunction during chronic infection. Immunity 2014, 40:289-302.
10. Brooks D.G., Teyton L., Oldstone M.B., McGavern D.B. Intrinsic functional dysregulation of CD4 T cells occurs rapidly following persistent viral infection. J. Virol. 2005, 79:10514-10527.
11. Elsaesser H., Sauer K., Brooks D.G. IL-21 is required to control chronic viral infection. Science 2009, 324:1569-1572.
12. Paley M.A., Kroy D.C., Odorizzi P.M., Johnnidis J.B., Dolfi D.V., Barnett B.E., et al. Progenitor and terminal subsets of CD8+ T cells cooperate to contain chronic viral infection. Science 2012, 338:1220-1225.
13. Wilson E.B., Brooks D.G. The role of IL-10 in regulating immunity to persistent viral infections. Curr. Top. Microbiol. Immunol. 2011, 350:39-65.
14. Donnelly R.P., Sheikh F., Kotenko S.V., Dickensheets H. The expanded family of class II cytokines that share the IL-10 receptor-2 (IL-10R2) chain. J. Leukoc. Biol. 2004, 76:314-321.
15. Kotenko S.V., Krause C.D., Izotova L.S., Pollack B.P., Wu W., Pestka S. Identification and functional characterization of a second chain of the interleukin-10 receptor complex. EMBO J. 1997, 16:5894-5903.
16. Moore K.W., de Waal Malefyt R., Coffman R.L., O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 2001, 19:683-765.
17. Finbloom D.S., Winestock K.D. IL-10 induces the tyrosine phosphorylation of tyk2 and Jak1 and the differential assembly of STAT1 alpha and STAT3 complexes in human T cells and monocytes. J. Immunol. 1995, 155:1079-1090.
18. Lai C.F., Ripperger J., Morella K.K., Jurlander J., Hawley T.S., Carson W.E., et al. Receptors for interleukin (IL)-10 and IL-6-type cytokines use similar signaling mechanisms for inducing transcription through IL-6 response elements. J. Biol. Chem. 1996, 271:13968-13975.
19. Wehinger J., Gouilleux F., Groner B., Finke J., Mertelsmann R., Weber-Nordt R.M. IL-10 induces DNA binding activity of three STAT proteins (Stat1, Stat3, and Stat5) and their distinct combinatorial assembly in the promoters of selected genes. FEBS Lett. 1996, 394:365-370.
20. Weber-Nordt R.M., Riley J.K., Greenlund A.C., Moore K.W., Darnell J.E., Schreiber R.D. Stat3 recruitment by two distinct ligand-induced, tyrosine-phosphorylated docking sites in the interleukin-10 receptor intracellular domain. J. Biol. Chem. 1996, 271:27954-27961.
21. Woitas R.P., Petersen U., Moshage D., Brackmann H.H., Matz B., Sauerbruch T., et al. HCV-specific cytokine induction in monocytes of patients with different outcomes of hepatitis C. World J. Gastroenterol.: WJG 2002, 8:562-566.
22. Hofer H., Neufeld J.B., Oesterreicher C., Grundtner P., Wrba F., Gangl A., et al. Bi-allelic presence of the interleukin-10 receptor 1 G330R allele is associated with cirrhosis in chronic HCV-1 infection. Genes Immun. 2005, 6:242-247.
23. Graziosi C., Pantaleo G., Gantt K.R., Fortin J.P., Demarest J.F., Cohen O.J., et al. Lack of evidence for the dichotomy of TH1 and TH2 predominance in HIV-infected individuals. Science 1994, 265:248-252.
24. Clerici M., Fusi M.L., Ruzzante S., Piconi S., Biasin M., Arienti D., et al. Type 1 and type 2 cytokines in HIV infection - a possible role in apoptosis and disease progression. Ann. Med. 1997, 29:185-188.
25. Swaminathan S. Molecular biology of Epstein-Barr virus and Kaposi's sarcoma-associated herpesvirus. Semin. Hematol. 2003, 40:107-115.
26. Cheong J.Y., Cho S.W., Hwang I.L., Yoon S.K., Lee J.H., Park C.S., et al. Association between chronic hepatitis B virus infection and interleukin-10, tumor necrosis factor-alpha gene promoter polymorphisms. J. Gastroenterol. Hepatol. 2006, 21:1163-1169.
27. Helminen M., Lahdenpohja N., Hurme M. Polymorphism of the interleukin-10 gene is associated with susceptibility to Epstein-Barr virus infection. J. Infect. Dis. 1999, 180:496-499.
28. Paladino N., Fainboim H., Theiler G., Schroder T., Munoz A.E., Flores A.C., et al. Gender susceptibility to chronic hepatitis C virus infection associated with interleukin 10 promoter polymorphism. J. Virol. 2006, 80:9144-9150.
29. Shin H.D., Winkler C., Stephens J.C., Bream J., Young H., Goedert J.J., et al. Genetic restriction of HIV-1 pathogenesis to AIDS by promoter alleles of IL10. Proc. Natl. Acad. Sci. USA 2000, 97:14467-14472.
30. Miyazoe S., Hamasaki K., Nakata K., Kajiya Y., Kitajima K., Nakao K., et al. Influence of interleukin-10 gene promoter polymorphisms on disease progression in patients chronically infected with hepatitis B virus. Am. J. Gastroenterol. 2002, 97:2086-2092.
31. Persico M., Capasso M., Persico E., Masarone M., Renzo A., Spano D., et al. Interleukin-10 - 1082 GG polymorphism influences the occurrence and the clinical characteristics of hepatitis C virus infection. J. Hepatol. 2006, 45:779-785.
32. Knapp S., Hennig B.J., Frodsham A.J., Zhang L., Hellier S., Wright M., et al. Interleukin-10 promoter polymorphisms and the outcome of hepatitis C virus infection. Immunogenetics 2003, 55:362-369.
33. Slobedman B., Barry P.A., Spencer J.V., Avdic S., Abendroth A. Virus-encoded homologs of cellular interleukin-10 and their control of host immune function. J. Virol. 2009, 83:9618-9629.
34. Brockman M.A., Kwon D.S., Tighe D.P., Pavlik D.F., Rosato P.C., Sela J., et al. IL-10 is up-regulated in multiple cell types during viremic HIV infection and reversibly inhibits virus-specific T cells. Blood 2009, 114:346-356.
35. Clerici M., Wynn T.A., Berzofsky J.A., Blatt S.P., Hendrix C.W., Sher A., et al. Role of interleukin-10 in T helper cell dysfunction in asymptomatic individuals infected with the human immunodeficiency virus. J. Clin. Invest. 1994, 93:768-775.
36. Landay A.L., Clerici M., Hashemi F., Kessler H., Berzofsky J.A., Shearer G.M. In vitro restoration of T cell immune function in human immunodeficiency virus-positive persons: effects of interleukin (IL)-12 and anti-IL-10. J. Infect. Dis. 1996, 173:1085-1091.
37. Said E.A., Dupuy F.P., Trautmann L., Zhang Y., Shi Y., El-Far M., et al. Programmed death-1-induced interleukin-10 production by monocytes impairs CD4+ T cell activation during HIV infection. Nat. Med. 2010, 16:452-459.
38. Rigopoulou E.I., Abbott W.G., Haigh P., Naoumov N.V. Blocking of interleukin-10 receptor - a novel approach to stimulate T-helper cell type 1 responses to hepatitis C virus. Clin. Immunol. 2005, 117:57-64.
39. Dong H., Zhu G., Tamada K., Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat. Med. 1999, 5:1365-1369.
40. Brooks D.G., Trifilo M.J., Edelmann K.H., Teyton L., McGavern D.B., Oldstone M.B. Interleukin-10 determines viral clearance or persistence in vivo. Nat. Med. 2006, 12:1301-1309.
41. Ejrnaes M., Filippi C.M., Martinic M.M., Ling E.M., Togher L.M., Crotty S., et al. Resolution of a chronic viral infection after interleukin-10 receptor blockade. J. Exp. Med. 2006, 203:2461-2472.
42. Ahmed R., Salmi A., Butler L.D., Chiller J.M., Oldstone M.B. Selection of genetic variants of lymphocytic choriomeningitis virus in spleens of persistently infected mice. Role in suppression of cytotoxic T lymphocyte response and viral persistence. J. Exp. Med. 1984, 160:521-540.
43. Wherry E.J., Blattman J.N., Murali-Krishna K., van der Most R., Ahmed R. Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J. Virol. 2003, 77:4911-4927.
44. Brooks D.G., Ha S.J., Elsaesser H., Sharpe A.H., Freeman G.J., Oldstone M.B. IL-10 and PD-L1 operate through distinct pathways to suppress T-cell activity during persistent viral infection. Proc. Natl. Acad. Sci. USA 2008, 105:20428-20433.
45. Steinbrink K., Wolfl M., Jonuleit H., Knop J., Enk A.H. Induction of tolerance by IL-10-treated dendritic cells. J. Immunol. 1997, 159:4772-4780.
46. Kajino K., Nakamura I., Bamba H., Sawai T., Ogasawara K. Involvement of IL-10 in exhaustion of myeloid dendritic cells and rescue by CD40 stimulation. Immunology 2007, 120:28-37.
47. Carbonneil C., Donkova-Petrini V., Aouba A., Weiss L. Defective dendritic cell function in HIV-infected patients receiving effective highly active antiretroviral therapy: neutralization of IL-10 production and depletion of CD4+CD25+ T cells restore high levels of HIV-specific CD4+ T cell responses induced by dendritic cells generated in the presence of IFN-alpha. J. Immunol. 2004, 172:7832-7840.
48. Foulds K.E., Rotte M.J., Seder R.A. IL-10 is required for optimal CD8 T cell memory following Listeria monocytogenes infection. J. Immunol. 2006, 177:2565-2574.
49. Groux H., Bigler M., de Vries J.E., Roncarolo M.G. Inhibitory and stimulatory effects of IL-10 on human CD8+ T cells. J. Immunol. 1998, 160:3188-3193.
50. Kang S.S., Allen P.M. Priming in the presence of IL-10 results in direct enhancement of CD8+ T cell primary responses and inhibition of secondary responses. J. Immunol. 2005, 174:5382-5389.
51. Govinden R., Bhoola K.D. Genealogy, expression, and cellular function of transforming growth factor-beta. Pharmacol. Ther. 2003, 98:257-265.
52. Kehrl J.H., Wakefield L.M., Roberts A.B., Jakowlew S., Alvarez-Mon M., Derynck R., et al. Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth. J. Exp. Med. 1986, 163:1037-1050.
53. Letterio J.J., Roberts A.B. Regulation of immune responses by TGF-beta. Annu. Rev. Immunol. 1998, 16:137-161.
54. Lagneaux L., Delforge A., Dorval C., Bron D., Stryckmans P. Excessive production of transforming growth factor-beta by bone marrow stromal cells in B-cell chronic lymphocytic leukemia inhibits growth of hematopoietic precursors and interleukin-6 production. Blood 1993, 82:2379-2385.
55. Filer A., Pitzalis C., Buckley C.D. Targeting the stromal microenvironment in chronic inflammation. Curr. Opin. Pharmacol. 2006, 6:393-400.
56. Annes J.P., Munger J.S., Rifkin D.B. Making sense of latent TGFbeta activation. J. Cell Sci. 2003, 116:217-224.
57. Nunes I., Shapiro R.L., Rifkin D.B. Characterization of latent TGF-beta activation by murine peritoneal macrophages. J. Immunol. 1995, 155:1450-1459.
58. Shi Y., Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 2003, 113:685-700.
59. Massague J. TGF-beta signal transduction. Annu. Rev. Biochem. 1998, 67:753-791.
60. Massague J. How cells read TGF-beta signals. Nat. Rev. Mol. Cell Biol. 2000, 1:169-178.
61. Inman G.J., Nicolas F.J., Hill C.S. Nucleocytoplasmic shuttling of Smads 2, 3, and 4 permits sensing of TGF-beta receptor activity. Mol. Cell 2002, 10:283-294.
62. Shi Y., Wang Y.F., Jayaraman L., Yang H., Massague J., Pavletich N.P. Crystal structure of a Smad MH1 domain bound to DNA: insights on DNA binding in TGF-beta signaling. Cell 1998, 94:585-594.
63. Zawel L., Dai J.L., Buckhaults P., Zhou S., Kinzler K.W., Vogelstein B., et al. Human Smad3 and Smad4 are sequence-specific transcription activators. Mol. Cell 1998, 1:611-617.
64. Xu L., Chen Y.G., Massague J. The nuclear import function of Smad2 is masked by SARA and unmasked by TGFbeta-dependent phosphorylation. Nat. Cell. Biol. 2000, 2:559-562.
65. Xu L., Kang Y., Col S., Massague J. Smad2 nucleocytoplasmic shuttling by nucleoporins CAN/Nup214 and Nup153 feeds TGFbeta signaling complexes in the cytoplasm and nucleus. Mol. Cell 2002, 10:271-282.
66. Li M.O., Wan Y.Y., Sanjabi S., Robertson A.K., Flavell R.A. Transforming growth factor-beta regulation of immune responses. Annu. Rev. Immunol. 2006, 24:99-146.
67. Kulkarni A.B., Huh C.G., Becker D., Geiser A., Lyght M., Flanders K.C., et al. Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc. Natl. Acad. Sci. USA 1993, 90:770-774.
68. Shull M.M., Ormsby I., Kier A.B., Pawlowski S., Diebold R.J., Yin M., et al. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 1992, 359:693-699.
69. Kobayashi S., Yoshida K., Ward J.M., Letterio J.J., Longenecker G., Yaswen L., et al. Beta 2-microglobulin-deficient background ameliorates lethal phenotype of the TGF-beta 1 null mouse. J. Immunol. 1999, 163:4013-4019.
70. Letterio J.J., Geiser A.G., Kulkarni A.B., Dang H., Kong L., Nakabayashi T., et al. Autoimmunity associated with TGF-beta1-deficiency in mice is dependent on MHC class II antigen expression. J. Clin. Invest. 1996, 98:2109-2119.
71. Marie J.C., Liggitt D., Rudensky A.Y. Cellular mechanisms of fatal early-onset autoimmunity in mice with the T cell-specific targeting of transforming growth factor-beta receptor. Immunity 2006, 25:441-454.
72. Lucas P.J., Kim S.J., Melby S.J., Gress R.E. Disruption of T cell homeostasis in mice expressing a T cell-specific dominant negative transforming growth factor beta II receptor. J. Exp. Med. 2000, 191:1187-1196.
73. Lin J.T., Martin S.L., Xia L., Gorham J.D. TGF-beta 1 uses distinct mechanisms to inhibit IFN-gamma expression in CD4+ T cells at priming and at recall: differential involvement of Stat4 and T-bet. J. Immunol. 2005, 174:5950-5958.
74. Smyth M.J., Strobl S.L., Young H.A., Ortaldo J.R., Ochoa A.C. Regulation of lymphokine-activated killer activity and pore-forming protein gene expression in human peripheral blood CD8+ T lymphocytes. Inhibition by transforming growth factor-beta. J. Immunol. 1991, 146:3289-3297.
75. Ahmadzadeh M., Johnson L.A., Heemskerk B., Wunderlich J.R., Dudley M.E., White D.E., et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 2009, 114:1537-1544.
76. Chen M.L., Pittet M.J., Gorelik L., Flavell R.A., Weissleder R., von Boehmer H., et al. Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo. Proc. Natl. Acad. Sci. USA 2005, 102:419-424.
77. Mempel T.R., Pittet M.J., Khazaie K., Weninger W., Weissleder R., von Boehmer H., et al. Regulatory T cells reversibly suppress cytotoxic T cell function independent of effector differentiation. Immunity 2006, 25:129-141.
78. Gorelik L., Constant S., Flavell R.A. Mechanism of transforming growth factor beta-induced inhibition of T helper type 1 differentiation. J. Exp. Med. 2002, 195:1499-1505.
79. Kao C., Oestreich K.J., Paley M.A., Crawford A., Angelosanto J.M., Ali M.A., et al. Transcription factor T-bet represses expression of the inhibitory receptor PD-1 and sustains virus-specific CD8+ T cell responses during chronic infection. Nat. Immunol. 2011, 12:663-671.
80. Tinoco R., Alcalde V., Yang Y., Sauer K., Zuniga E.I. Cell-intrinsic transforming growth factor-beta signaling mediates virus-specific CD8+ T cell deletion and viral persistence in vivo. Immunity 2009, 31:145-157.
81. Malherbe G., Steel H.C., Cassol S., de Oliveira T., Seebregts C.J., Anderson R., et al. Circulating biomarkers of immune activation distinguish viral suppression from nonsuppression in HAART-treated patients with advanced HIV-1 subtype C infection. Mediat. Inflamm. 2014, 2014:198413.
82. Kekow J., Wachsman W., McCutchan J.A., Gross W.L., Zachariah M., Carson D.A., et al. Transforming growth factor-beta and suppression of humoral immune responses in HIV infection. J. Clin. Invest. 1991, 87:1010-1016.
83. Nelson D.R., Gonzalez-Peralta R.P., Qian K., Xu Y., Marousis C.G., Davis G.L., et al. Transforming growth factor-beta 1 in chronic hepatitis C. J. Viral Hepatitis 1997, 4:29-35.
84. Grayson J.M., Weant A.E., Holbrook B.C., Hildeman D. Role of Bim in regulating CD8+ T-cell responses during chronic viral infection. J. Virol. 2006, 80:8627-8638.
85. Hughes P.D., Belz G.T., Fortner K.A., Budd R.C., Strasser A., Bouillet P. Apoptosis regulators Fas and Bim cooperate in shutdown of chronic immune responses and prevention of autoimmunity. Immunity 2008, 28:197-205.
86. Boettler T., Cheng Y., Ehrhardt K., von Herrath M. TGF-beta blockade does not improve control of an established persistent viral infection. Viral Immunol. 2012, 25:232-238.
87. Garidou L., Heydari S., Gossa S., McGavern D.B. Therapeutic blockade of transforming growth factor beta fails to promote clearance of a persistent viral infection. J. Virol. 2012, 86:7060-7071.
88. Colonna M., Trinchieri G., Liu Y.J. Plasmacytoid dendritic cells in immunity. Nat. Immunol. 2004, 5:1219-1226.
89. McNab F., Mayer-Barber K., Sher A., Wack A., O'Garra A. Type I interferons in infectious disease. Nat. Rev. Immunol. 2015, 15:87-103.
90. Ivashkiv L.B., Donlin L.T. Regulation of type I interferon responses. Nat. Rev. Immunol. 2014, 14:36-49.
91. Schoggins J.W., Wilson S.J., Panis M., Murphy M.Y., Jones C.T., Bieniasz P., et al. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 2011, 472:481-485.
92. Yan N., Chen Z.J. Intrinsic antiviral immunity. Nat. Immunol. 2012, 13:214-222.
93. Boasso A., Shearer G.M. Chronic innate immune activation as a cause of HIV-1 immunopathogenesis. Clin. Immunol. 2008, 126:235-242.
94. Hardy G.A., Sieg S., Rodriguez B., Anthony D., Asaad R., Jiang W., et al. Interferon-alpha is the primary plasma type-I IFN in HIV-1 infection and correlates with immune activation and disease markers. PLoS ONE 2013, 8:e56527.
95. Sedaghat A.R., German J., Teslovich T.M., Cofrancesco J., Jie C.C., Talbot C.C., et al. Chronic CD4+ T-cell activation and depletion in human immunodeficiency virus type 1 infection: type I interferon-mediated disruption of T-cell dynamics. J. Virol. 2008, 82:1870-1883.
96. Stylianou E., Aukrust P., Bendtzen K., Muller F., Froland S.S. Interferons and interferon (IFN)-inducible protein 10 during highly active anti-retroviral therapy (HAART)-possible immunosuppressive role of IFN-alpha in HIV infection. Clin. Exp. Immunol. 2000, 119:479-485.
97. Hyrcza M.D., Kovacs C., Loutfy M., Halpenny R., Heisler L., Yang S., et al. Distinct transcriptional profiles in ex vivo CD4+ and CD8+ T cells are established early in human immunodeficiency virus type 1 infection and are characterized by a chronic interferon response as well as extensive transcriptional changes in CD8+ T cells. J. Virol. 2007, 81:3477-3486.
98. Rotger M., Dalmau J., Rauch A., McLaren P., Bosinger S.E., Martinez R., et al. Comparative transcriptomics of extreme phenotypes of human HIV-1 infection and SIV infection in sooty mangabey and rhesus macaque. J. Clin. Invest. 2011, 121:2391-2400.
99. Jacquelin B., Mayau V., Targat B., Liovat A.S., Kunkel D., Petitjean G., et al. Nonpathogenic SIV infection of African green monkeys induces a strong but rapidly controlled type I IFN response. J. Clin. Invest. 2009, 119:3544-3555.
100. Estes J.D., Gordon S.N., Zeng M., Chahroudi A.M., Dunham R.M., Staprans S.I., et al. Early resolution of acute immune activation and induction of PD-1 in SIV-infected sooty mangabeys distinguishes nonpathogenic from pathogenic infection in rhesus macaques. J. Immunol. 2008, 180:6798-6807.
101. Arimori Y., Nakamura R., Yamada H., Shibata K., Maeda N., Kase T., et al. Type I interferon limits influenza virus-induced acute lung injury by regulation of excessive inflammation in mice. Antiviral Res. 2013, 99:230-237.
102. Schreiner B., Mitsdoerffer M., Kieseier B.C., Chen L., Hartung H.P., Weller M., et al. Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis. J. Neuroimmunol. 2004, 155:172-182.
103. Rudick R.A., Goodkin D.E., Jacobs L.D., Cookfair D.L., Herndon R.M., Richert J.R., et al. Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. 1997. Neurology 2001, 57:S25-S30.
104. Marshall H.D., Urban S.L., Welsh R.M. Virus-induced transient immune suppression and the inhibition of T cell proliferation by type I interferon. J. Virol. 2011, 85:5929-5939.
105. Kaser A., Nagata S., Tilg H. Interferon alpha augments activation-induced T cell death by upregulation of Fas (CD95/APO-1) and Fas ligand expression. Cytokine 1999, 11:736-743.
106. Nguyen K.B., Cousens L.P., Doughty L.A., Pien G.C., Durbin J.E., Biron C.A. Interferon alpha/beta-mediated inhibition and promotion of interferon gamma: STAT1 resolves a paradox. Nat. Immunol. 2000, 1:70-76.
107. Teijaro J.R., Ng C., Lee A.M., Sullivan B.M., Sheehan K.C., Welch M., et al. Persistent LCMV infection is controlled by blockade of type I interferon signaling. Science 2013, 340:207-211.
108. Wilson E.B., Yamada D.H., Elsaesser H., Herskovitz J., Deng J., Cheng G., et al. Blockade of chronic type I interferon signaling to control persistent LCMV infection. Science 2013, 340:202-207.
109. Bolen C.R., Robek M.D., Brodsky L., Schulz V., Lim J.K., Taylor M.W., et al. The blood transcriptional signature of chronic hepatitis C virus is consistent with an ongoing interferon-mediated antiviral response. J. Interferon Cytokine Res.: Off. J. Int. Soc. Interferon Cytokine Res. 2013, 33:15-23.
110. Wang Y., Swiecki M., Cella M., Alber G., Schreiber R.D., Gilfillan S., et al. Timing and magnitude of type I interferon responses by distinct sensors impact CD8 T cell exhaustion and chronic viral infection. Cell Host Microbe 2012, 11:631-642.
111. Heim M.H. 25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end. Nat. Rev. Immunol. 2013, 13:535-542.
112. Wilson E.B., Brooks D.G. Decoding the complexity of type I interferon to treat persistent viral infections. Trends Microbiol. 2013, 21:634-640.
113. Ng C.T., Sullivan B.M., Teijaro J.R., Lee A.M., Welch M., Rice S., et al. Blockade of interferon Beta, but not interferon alpha, signaling controls persistent viral infection. Cell Host Microbe 2015, 17:653-661.
114. Silver J.S., Hunter C.A. Gp130 at the nexus of inflammation, autoimmunity, and cancer. J. Leukoc. Biol. 2010, 88:1145-1156.
115. Taga T., Kishimoto T. Gp130 and the interleukin-6 family of cytokines. Annu. Rev. Immunol. 1997, 15:797-819.
116. Stahl N., Boulton T.G., Farruggella T., Ip N.Y., Davis S., Witthuhn B.A., et al. Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 beta receptor components. Science 1994, 263:92-95.
117. Lutticken C., Wegenka U.M., Yuan J., Buschmann J., Schindler C., Ziemiecki A., et al. Association of transcription factor APRF and protein kinase Jak1 with the interleukin-6 signal transducer gp130. Science 1994, 263:89-92.
118. Takahashi-Tezuka M., Yoshida Y., Fukada T., Ohtani T., Yamanaka Y., Nishida K., et al. Gab1 acts as an adapter molecule linking the cytokine receptor gp130 to ERK mitogen-activated protein kinase. Mol. Cell. Biol. 1998, 18:4109-4117.
119. Heinrich P.C., Behrmann I., Haan S., Hermanns H.M., Muller-Newen G., Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem. J. 2003, 374:1-20.
120. Saito M., Yoshida K., Hibi M., Taga T., Kishimoto T. Molecular cloning of a murine IL-6 receptor-associated signal transducer, gp130, and its regulated expression in vivo. J. Immunol. 1992, 148:4066-4071.
121. Yao X., Huang J., Zhong H., Shen N., Faggioni R., Fung M., et al. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers. Pharmacol. Ther. 2014, 141:125-139.
122. Romani L., Mencacci A., Cenci E., Spaccapelo R., Toniatti C., Puccetti P., et al. Impaired neutrophil response and CD4+ T helper cell 1 development in interleukin 6-deficient mice infected with Candida albicans. J. Exp. Med. 1996, 183:1345-1355.
123. Dalrymple S.A., Slattery R., Aud D.M., Krishna M., Lucian L.A., Murray R. Interleukin-6 is required for a protective immune response to systemic Escherichia coli infection. Infect. Immun. 1996, 64:3231-3235.
124. Suzuki Y., Rani S., Liesenfeld O., Kojima T., Lim S., Nguyen T.A., et al. Impaired resistance to the development of toxoplasmic encephalitis in interleukin-6-deficient mice. Infect. Immun. 1997, 65:2339-2345.
125. Kopf M., Baumann H., Freer G., Freudenberg M., Lamers M., Kishimoto T., et al. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 1994, 368:339-342.
126. Jebbari H., Roberts C.W., Ferguson D.J., Bluethmann H., Alexander J. A protective role for IL-6 during early infection with Toxoplasma gondii. Parasite Immunol. 1998, 20:231-239.
127. Ladel C.H., Blum C., Dreher A., Reifenberg K., Kopf M., Kaufmann S.H. Lethal tuberculosis in interleukin-6-deficient mutant mice. Infect. Immun. 1997, 65:4843-4849.
128. van der Poll T., Keogh C.V., Guirao X., Buurman W.A., Kopf M., Lowry S.F. Interleukin-6 gene-deficient mice show impaired defense against pneumococcal pneumonia. J. Infect. Dis. 1997, 176:439-444.
129. Hunter C.A., Jones S.A. IL-6 as a keystone cytokine in health and disease. Nat. Immunol. 2015, 16:448-457.
130. Modur V., Li Y., Zimmerman G.A., Prescott S.M., McIntyre T.M. Retrograde inflammatory signaling from neutrophils to endothelial cells by soluble interleukin-6 receptor alpha. J. Clin. Invest. 1997, 100:2752-2756.
131. McLoughlin R.M., Hurst S.M., Nowell M.A., Harris D.A., Horiuchi S., Morgan L.W., et al. Differential regulation of neutrophil-activating chemokines by IL-6 and its soluble receptor isoforms. J. Immunol. 2004, 172:5676-5683.
132. Hurst S.M., Wilkinson T.S., McLoughlin R.M., Jones S., Horiuchi S., Yamamoto N., et al. Il-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity 2001, 14:705-714.
133. Lauder S.N., Jones E., Smart K., Bloom A., Williams A.S., Hindley J.P., et al. Interleukin-6 limits influenza-induced inflammation and protects against fatal lung pathology. Eur. J. Immunol. 2013, 43:2613-2625.
134. Villarino A., Hibbert L., Lieberman L., Wilson E., Mak T., Yoshida H., et al. The IL-27R (WSX-1) is required to suppress T cell hyperactivity during infection. Immunity 2003, 19:645-655.
135. Choi Y.S., Eto D., Yang J.A., Lao C., Crotty S. Cutting edge: STAT1 is required for IL-6-mediated Bcl6 induction for early follicular helper cell differentiation. J. Immunol. 2013, 190:3049-3053.
136. Eto D., Lao C., DiToro D., Barnett B., Escobar T.C., Kageyama R., et al. IL-21 and IL-6 are critical for different aspects of B cell immunity and redundantly induce optimal follicular helper CD4 T cell (Tfh) differentiation. PLoS ONE 2011, 6:e17739.
137. Fahey L.M., Wilson E.B., Elsaesser H., Fistonich C.D., McGavern D.B., Brooks D.G. Viral persistence redirects CD4 T cell differentiation toward T follicular helper cells. J. Exp. Med. 2011, 208:987-999.
138. Suto A., Kashiwakuma D., Kagami S., Hirose K., Watanabe N., Yokote K., et al. Development and characterization of IL-21-producing CD4+ T cells. J. Exp. Med. 2008, 205:1369-1379.
139. Dienz O., Eaton S.M., Bond J.P., Neveu W., Moquin D., Noubade R., et al. The induction of antibody production by IL-6 is indirectly mediated by IL-21 produced by CD4+ T cells. J. Exp. Med. 2009, 206:69-78.
140. Eddahri F., Denanglaire S., Bureau F., Spolski R., Leonard W.J., Leo O., et al. Interleukin-6/STAT3 signaling regulates the ability of naive T cells to acquire B-cell help capacities. Blood 2009, 113:2426-2433.
141. Yi J.S., Du M., Zajac A.J. A vital role for interleukin-21 in the control of a chronic viral infection. Science 2009, 324:1572-1576.
142. Frohlich A., Kisielow J., Schmitz I., Freigang S., Shamshiev A.T., Weber J., et al. IL-21R on T cells is critical for sustained functionality and control of chronic viral infection. Science 2009, 324:1576-1580.
143. Wojno E.D., Hunter C.A. New directions in the basic and translational biology of interleukin-27. Trends Immunol. 2012, 33:91-97.
144. Birx D.L., Redfield R.R., Tencer K., Fowler A., Burke D.S., Tosato G. Induction of interleukin-6 during human immunodeficiency virus infection. Blood 1990, 76:2303-2310.
145. Spanakis N.E., Garinis G.A., Alexopoulos E.C., Patrinos G.P., Menounos P.G., Sklavounou A., et al. Cytokine serum levels in patients with chronic HCV infection. J. Clin. Lab. Anal. 2002, 16:40-46.
146. Torre D., Zeroli C., Giola M., Ferrario G., Fiori G.P., Bonetta G., et al. Serum levels of interleukin-1 alpha, interleukin-1 beta, interleukin-6, and tumor necrosis factor in patients with acute viral hepatitis. Clin. Infect. Dis.: Off. Publ. Infect. Dis. Soc. Am. 1994, 18:194-198.
147. Hafez A.Ashrafi, Vasmehjani A.Ahmadi, Baharlou R., Nasab S.D.Mousavi, Davami M.H., Najafi A., et al. Analytical assessment of interleukin - 23 and - 27 cytokines in healthy people and patients with hepatitis C virus infection (genotypes 1 and 3a). Hepatitis Month. 2014, 14:e21000.
148. He L., Zhao J., Wang M.H., Siu K.K., Gan Y.X., Chen L., et al. Interleukin-27 is differentially associated with HIV viral load and CD4+ T cell counts in therapy-naive HIV-mono-infected and HIV/HCV-co-infected Chinese. PLoS ONE 2014, 9:e96792.
149. Guzzo C., Hopman W.M., Mat N.F.Che, Wobeser W., Gee K. Impact of HIV infection, highly active antiretroviral therapy, and hepatitis C coinfection on serum interleukin-27. Aids 2010, 24:1371-1374.
150. Swaminathan S., Hu Z., Rupert A.W., Higgins J.M., Dewar R.L., Stevens R., et al. Plasma interleukin-27 (IL-27) levels are not modulated in patients with chronic HIV-1 infection. PLoS ONE 2014, 9:e98989.
151. Harker J.A., Dolgoter A., Zuniga E.I. Cell-intrinsic IL-27 and gp130 cytokine receptor signaling regulates virus-specific CD4(+) T cell responses and viral control during chronic infection. Immunity 2013, 39:548-559.
152. Harker J.A., Lewis G.M., Mack L., Zuniga E.I. Late interleukin-6 escalates T follicular helper cell responses and controls a chronic viral infection. Science 2011, 334:825-829.
153. Bergthaler A., Flatz L., Verschoor A., Hegazy A.N., Holdener M., Fink K., et al. Impaired antibody response causes persistence of prototypic T cell-contained virus. PLoS Biol. 2009, 7:e1000080.
154. Imamichi T., Yang J., Huang D.W., Brann T.W., Fullmer B.A., Adelsberger J.W., et al. IL-27, a novel anti-HIV cytokine, activates multiple interferon-inducible genes in macrophages. Aids 2008, 22:39-45.
155. Greenwell-Wild T., Vazquez N., Jin W., Rangel Z., Munson P.J., Wahl S.M. Interleukin-27 inhibition of HIV-1 involves an intermediate induction of type I interferon. Blood 2009, 114:1864-1874.
156. Dai L., Lidie K.B., Chen Q., Adelsberger J.W., Zheng X., Huang D., et al. IL-27 inhibits HIV-1 infection in human macrophages by down-regulating host factor SPTBN1 during monocyte to macrophage differentiation. J. Exp. Med. 2013, 210:517-534.
157. Chen Q., Swaminathan S., Yang D., Dai L., Sui H., Yang J., et al. Interleukin-27 is a potent inhibitor of cis HIV-1 replication in monocyte-derived dendritic cells via a type I interferon-independent pathway. PLoS ONE 2013, 8:e59194.
158. Rochman Y., Spolski R., Leonard W.J. New insights into the regulation of T cells by gamma(c) family cytokines. Nat. Rev. Immunol. 2009, 9:480-490.
159. Decaluwe H., Taillardet M., Corcuff E., Munitic I., Law H.K., Rocha B., et al. Gamma(c) deficiency precludes CD8+ T cell memory despite formation of potent T cell effectors. Proc. Natl. Acad. Sci. USA 2010, 107:9311-9316.
160. Surh C.D., Sprent J. Homeostasis of naive and memory T cells. Immunity 2008, 29:848-862.
161. Masse G.X., Corcuff E., Decaluwe H., Bommhardt U., Lantz O., Buer J., et al. Gamma(c) cytokines provide multiple homeostatic signals to naive CD4(+) T cells. Eur. J. Immunol. 2007, 37:2606-2616.
162. Mathieu C., Beltra J.C., Charpentier T., Bourbonnais S., Santo J.P., Lamarre A., et al. IL-2 and IL-15 regulate CD8 memory T-cell differentiation but are dispensable for protective recall responses. Eur. J. Immunol. 2015, 45:3324-3338.
163. Fewkes N.M., Mackall C.L. Novel gamma-chain cytokines as candidate immune modulators in immune therapies for cancer. Cancer J. 2010, 16:392-398.
164. Diallo M., Zheng Y., Chen X., He Y., Zhou H., Chen Z. Prospect of IL-2, IL-7, IL-15 and IL-21 for HIV immune-based therapy. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2011, 36:1037-1045.
165. Asao H., Okuyama C., Kumaki S., Ishii N., Tsuchiya S., Foster D., et al. Cutting edge: the common gamma-chain is an indispensable subunit of the IL-21 receptor complex. J. Immunol. 2001, 167:1-5.
166. Holm C., Nyvold C.G., Paludan S.R., Thomsen A.R., Hokland M. Interleukin-21 mRNA expression during virus infections. Cytokine 2006, 33:41-45.
167. Korn T., Bettelli E., Gao W., Awasthi A., Jager A., Strom T.B., et al. IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature 2007, 448:484-487.
168. Nurieva R., Yang X.O., Martinez G., Zhang Y., Panopoulos A.D., Ma L., et al. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature 2007, 448:480-483.
169. Spolski R., Leonard W.J. Interleukin-21: basic biology and implications for cancer and autoimmunity. Annu. Rev. Immunol. 2008, 26:57-79.
170. Battegay M., Moskophidis D., Rahemtulla A., Hengartner H., Mak T.W., Zinkernagel R.M. Enhanced establishment of a virus carrier state in adult CD4+ T-cell-deficient mice. J. Virol. 1994, 68:4700-4704.
171. Matloubian M., Concepcion R.J., Ahmed R. CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection. J. Virol. 1994, 68:8056-8063.
172. Aubert R.D., Kamphorst A.O., Sarkar S., Vezys V., Ha S.J., Barber D.L., et al. Antigen-specific CD4 T-cell help rescues exhausted CD8 T cells during chronic viral infection. Proc. Natl. Acad. Sci. USA 2011, 108:21182-21187.
173. Gerlach J.T., Diepolder H.M., Jung M.C., Gruener N.H., Schraut W.W., Zachoval R., et al. Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C. Gastroenterology 1999, 117:933-941.
174. Grakoui A., Shoukry N.H., Woollard D.J., Han J.H., Hanson H.L., Ghrayeb J., et al. HCV persistence and immune evasion in the absence of memory T cell help. Science 2003, 302:659-662.
175. Smyk-Pearson S., Tester I.A., Klarquist J., Palmer B.E., Pawlotsky J.M., Golden-Mason L., et al. Spontaneous recovery in acute human hepatitis C virus infection: functional T-cell thresholds and relative importance of CD4 help. J. Virol. 2008, 82:1827-1837.
176. Puel A., Ziegler S.F., Buckley R.H., Leonard W.J. Defective IL7R expression in T(-)B(+)NK(+) severe combined immunodeficiency. Nat. Genet. 1998, 20:394-397.
177. Tan J.T., Dudl E., LeRoy E., Murray R., Sprent J., Weinberg K.I., et al. IL-7 is critical for homeostatic proliferation and survival of naive T cells. Proc. Natl. Acad. Sci. USA 2001, 98:8732-8737.
178. Takada K., Jameson S.C. Naive T cell homeostasis: from awareness of space to a sense of place. Nat. Rev. Immunol. 2009, 9:823-832.
179. Hand T.W., Morre M., Kaech S.M. Expression of IL-7 receptor alpha is necessary but not sufficient for the formation of memory CD8 T cells during viral infection. Proc. Natl. Acad. Sci. USA 2007, 104:11730-11735.
180. Bradley L.M., Haynes L., Swain S.L. IL-7: maintaining T-cell memory and achieving homeostasis. Trends Immunol. 2005, 26:172-176.
181. Schluns K.S., Kieper W.C., Jameson S.C., Lefrancois L. Interleukin-7 mediates the homeostasis of naive and memory CD8 T cells in vivo. Nat. Immunol. 2000, 1:426-432.
182. Kittipatarin C., Khaled A.R. Interlinking interleukin-7. Cytokine 2007, 39:75-83.
183. Sprent J., Cho J.H., Boyman O., Surh C.D. T cell homeostasis. Immunol. Cell Biol. 2008, 86:312-319.
184. Jiang Q., Li W.Q., Aiello F.B., Mazzucchelli R., Asefa B., Khaled A.R., et al. Cell biology of IL-7, a key lymphotrophin. Cytokine Growth Factor Rev. 2005, 16:513-533.
185. Wojciechowski S., Tripathi P., Bourdeau T., Acero L., Grimes H.L., Katz J.D., et al. Bim/Bcl-2 balance is critical for maintaining naive and memory T cell homeostasis. J. Exp. Med. 2007, 204:1665-1675.
186. Levy Y., Lacabaratz C., Weiss L., Viard J.P., Goujard C., Lelievre J.D., et al. Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment. J. Clin. Invest. 2009, 119:997-1007.
187. Sereti I., Dunham R.M., Spritzler J., Aga E., Proschan M.A., Medvik K., et al. IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection. Blood 2009, 113:6304-6314.
188. Fry T.J., Moniuszko M., Creekmore S., Donohue S.J., Douek D.C., Giardina S., et al. IL-7 therapy dramatically alters peripheral T-cell homeostasis in normal and SIV-infected nonhuman primates. Blood 2003, 101:2294-2299.
189. Nugeyre M.T., Monceaux V., Beq S., Cumont M.C., Fang R.Ho Tsong, Chene L., et al. IL-7 stimulates T cell renewal without increasing viral replication in simian immunodeficiency virus-infected macaques. J. Immunol. 2003, 171:4447-4453.
190. Beq S., Nugeyre M.T., Fang R.Ho Tsong, Gautier D., Legrand R., Schmitt N., et al. IL-7 induces immunological improvement in SIV-infected rhesus macaques under antiviral therapy. J. Immunol. 2006, 176:914-922.
191. Chu Y.W., Memon S.A., Sharrow S.O., Hakim F.T., Eckhaus M., Lucas P.J., et al. Exogenous IL-7 increases recent thymic emigrants in peripheral lymphoid tissue without enhanced thymic function. Blood 2004, 104:1110-1119.
192. Pellegrini M., Calzascia T., Elford A.R., Shahinian A., Lin A.E., Dissanayake D., et al. Adjuvant IL-7 antagonizes multiple cellular and molecular inhibitory networks to enhance immunotherapies. Nat. Med. 2009, 15:528-536.
193. Lang K.S., Recher M., Navarini A.A., Harris N.L., Lohning M., Junt T., et al. Inverse correlation between IL-7 receptor expression and CD8 T cell exhaustion during persistent antigen stimulation. Eur. J. Immunol. 2005, 35:738-745.
194. Nanjappa S.G., Kim E.H., Suresh M. Immunotherapeutic effects of IL-7 during a chronic viral infection in mice. Blood 2011, 117:5123-5132.
195. Pellegrini M., Calzascia T., Toe J.G., Preston S.P., Lin A.E., Elford A.R., et al. IL-7 engages multiple mechanisms to overcome chronic viral infection and limit organ pathology. Cell 2011, 144:601-613.
196. Radaeva S., Sun R., Pan H.N., Hong F., Gao B. Interleukin 22 (IL-22) plays a protective role in T cell-mediated murine hepatitis: IL-22 is a survival factor for hepatocytes via STAT3 activation. Hepatology 2004, 39:1332-1342.
197. Zenewicz L.A., Yancopoulos G.D., Valenzuela D.M., Murphy A.J., Karow M., Flavell R.A. Interleukin-22 but not interleukin-17 provides protection to hepatocytes during acute liver inflammation. Immunity 2007, 27:647-659.
198. Croker B.A., Krebs D.L., Zhang J.G., Wormald S., Willson T.A., Stanley E.G., et al. SOCS3 negatively regulates IL-6 signaling in vivo. Nat. Immunol. 2003, 4:540-545.
199. Pfizenmaier K., Scheurich P., Daubener W., Kronke M., Rollinghoff M., Wagner H. Quantitative representation of all T cells committed to develop into cytotoxic effector cells and/or interleukin 2 activity-producing helper cells within murine T lymphocyte subsets. Eur. J. Immunol. 1984, 14:33-39.
200. D'Souza W.N., Lefrancois L. Frontline: an in-depth evaluation of the production of IL-2 by antigen-specific CD8 T cells in vivo. Eur. J. Immunol. 2004, 34:2977-2985.
201. Liao W., Lin J.X., Leonard W.J. Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity 2013, 38:13-25.
202. Boyman O., Sprent J. The role of interleukin-2 during homeostasis and activation of the immune system. Nat. Rev. Immunol. 2012, 12:180-190.
203. D'Souza W.N., Schluns K.S., Masopust D., Lefrancois L. Essential role for IL-2 in the regulation of antiviral extralymphoid CD8 T cell responses. J. Immunol. 2002, 168:5566-5572.
204. D'Souza W.N., Lefrancois L. IL-2 is not required for the initiation of CD8 T cell cycling but sustains expansion. J. Immunol. 2003, 171:5727-5735.
205. Williams M.A., Tyznik A.J., Bevan M.J. Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells. Nature 2006, 441:890-893.
206. Obar J.J., Molloy M.J., Jellison E.R., Stoklasek T.A., Zhang W., Usherwood E.J., et al. CD4+ T cell regulation of CD25 expression controls development of short-lived effector CD8+ T cells in primary and secondary responses. Proc. Natl. Acad. Sci. USA 2010, 107:193-198.
207. Kalia V., Sarkar S., Subramaniam S., Haining W.N., Smith K.A., Ahmed R. Prolonged interleukin-2Ralpha expression on virus-specific CD8+ T cells favors terminal-effector differentiation in vivo. Immunity 2010, 32:91-103.
208. Pipkin M.E., Sacks J.A., Cruz-Guilloty F., Lichtenheld M.G., Bevan M.J., Rao A. Interleukin-2 and inflammation induce distinct transcriptional programs that promote the differentiation of effector cytolytic T cells. Immunity 2010, 32:79-90.
209. Blattman J.N., Grayson J.M., Wherry E.J., Kaech S.M., Smith K.A., Ahmed R. Therapeutic use of IL-2 to enhance antiviral T-cell responses in vivo. Nat. Med. 2003, 9:540-547.
210. West E.E., Jin H.T., Rasheed A.U., Penaloza-Macmaster P., Ha S.J., Tan W.G., et al. PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells. J. Clin. Invest. 2013, 123:2604-2615.
211. Levy Y., Capitant C., Houhou S., Carriere I., Viard J.P., Goujard C., et al. Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: a randomised controlled trial. ANRS 048 study group. Lancet 1999, 353:1923-1929.
212. Hardy G.A., Imami N., Nelson M.R., Sullivan A.K., Moss R., Aasa-Chapman M.M., et al. A phase I, randomized study of combined IL-2 and therapeutic immunisation with antiretroviral therapy. J. Immune Therap. Vacc. 2007, 5:6.
213. Kovacs J.A., Vogel S., Albert J.M., Falloon J., Davey R.T., Walker R.E., et al. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. N. Engl. J. Med. 1996, 335:1350-1356.
214. Group I-ES, Committee SS, Abrams D., Levy Y., Losso M.H., Babiker A., et al. Interleukin-2 therapy in patients with HIV infection. N. Engl. J. Med. 2009, 361:1548-1559.
215. Pett S.L., Kelleher A.D., Emery S. Role of interleukin-2 in patients with HIV infection. Drugs 2010, 70:1115-1130.
216. Hinrichs C.S., Spolski R., Paulos C.M., Gattinoni L., Kerstann K.W., Palmer D.C., et al. IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy. Blood 2008, 111:5326-5333.
217. Mitchell D.M., Ravkov E.V., Williams M.A. Distinct roles for IL-2 and IL-15 in the differentiation and survival of CD8+ effector and memory T cells. J. Immunol. 2010, 184:6719-6730.
218. Yi J.S., Ingram J.T., Zajac A.J. IL-21 deficiency influences CD8 T cell quality and recall responses following an acute viral infection. J. Immunol. 2010, 185:4835-4845.